[go: up one dir, main page]

IN2014DN11156A - - Google Patents

Info

Publication number
IN2014DN11156A
IN2014DN11156A IN11156DEN2014A IN2014DN11156A IN 2014DN11156 A IN2014DN11156 A IN 2014DN11156A IN 11156DEN2014 A IN11156DEN2014 A IN 11156DEN2014A IN 2014DN11156 A IN2014DN11156 A IN 2014DN11156A
Authority
IN
India
Prior art keywords
analyzing
cell
contaminant
administration
nucleic acid
Prior art date
Application number
Other languages
English (en)
Inventor
Carl H June
Bruce L Levine
Michael D Kalos
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49916569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN11156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IN2014DN11156A publication Critical patent/IN2014DN11156A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
IN11156DEN2014 2012-07-13 2013-07-12 IN2014DN11156A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671495P 2012-07-13 2012-07-13
PCT/US2013/050287 WO2014011996A1 (fr) 2012-07-13 2013-07-12 Procédés d'évaluation de l'aptitude de lymphocytes t transduits à être administrés

Publications (1)

Publication Number Publication Date
IN2014DN11156A true IN2014DN11156A (fr) 2015-10-02

Family

ID=49916569

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11156DEN2014 IN2014DN11156A (fr) 2012-07-13 2013-07-12

Country Status (13)

Country Link
US (1) US9572836B2 (fr)
EP (2) EP3584256A1 (fr)
JP (2) JP6482461B2 (fr)
KR (3) KR102332322B1 (fr)
CN (2) CN104619723B (fr)
AU (3) AU2013289979A1 (fr)
BR (1) BR112015000505A2 (fr)
CA (1) CA2878862C (fr)
EA (1) EA028988B1 (fr)
ES (1) ES2733525T3 (fr)
IN (1) IN2014DN11156A (fr)
MX (2) MX370495B (fr)
WO (1) WO2014011996A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817331B1 (fr) * 2012-02-22 2023-08-30 The Trustees of the University of Pennsylvania Utilisation du domaine de signalisation de cd2 dans des récepteurs d'antigène chimère de deuxième génération
CN104254780B (zh) 2012-02-23 2017-04-12 朱诺治疗有限公司 细胞和其它复杂生物材料的色谱分离
EP4282419A1 (fr) 2012-12-20 2023-11-29 Purdue Research Foundation Cellules t exprimant un récepteur d'antigène chimérique et produits thérapeutiques anticancéreux
US9394368B2 (en) 2013-02-20 2016-07-19 Novartis Ag Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
WO2014130635A1 (fr) 2013-02-20 2014-08-28 Novartis Ag Ciblage efficace de la leucémie primaire humaine au moyen de lymphocytes t génétiquement modifiés des récepteurs d'antigènes chimériques anti-cd123
WO2014145252A2 (fr) 2013-03-15 2014-09-18 Milone Michael C Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
WO2015112626A1 (fr) 2014-01-21 2015-07-30 June Carl H Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
DK3888674T3 (da) 2014-04-07 2024-07-08 Novartis Ag Behandling af cancer ved anvendelse af anti-cd19-kimær antigenreceptor
IL280738B (en) 2014-04-16 2022-07-01 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
PT4219687T (pt) 2014-04-23 2024-10-02 Juno Therapeutics Inc Métodos para isolamento, cultura, e manipulação genetica de populações de células imunes para terapêutica adotiva
NZ725169A (en) 2014-04-25 2018-02-23 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
KR102485855B1 (ko) 2014-06-06 2023-01-09 2세븐티 바이오, 인코포레이티드 개선된 t 세포 조성물
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG11201700416TA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014535A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Traitement du cancer au moyen d'un récepteur d'antigènes chimériques cll-1
WO2016014789A2 (fr) 2014-07-24 2016-01-28 Bluebird Bio, Inc. Récepteurs de l'antigène chimérique bcma
WO2016028896A1 (fr) 2014-08-19 2016-02-25 Novartis Ag Récepteur d'antigène chimérique anti-cd123 (car) utilisé dans le traitement du cancer
CN107580628B (zh) 2014-09-17 2022-01-07 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
EP3640262A1 (fr) 2014-12-12 2020-04-22 Bluebird Bio, Inc. Récepteurs de l'antigène chimérique bcma destinés à être utilisés dans le traitement d'une malignité hématologique
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PT3280729T (pt) 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
SG10201914069SA (en) 2015-05-18 2020-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
CN104910279B (zh) * 2015-06-05 2019-02-22 重庆精准生物技术有限公司 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP3331913A1 (fr) 2015-08-07 2018-06-13 Novartis AG Traitement du cancer à l'aide des protéines de récepteur cd3 chimères
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
MX2018003463A (es) 2015-09-22 2018-09-06 Univ Pennsylvania Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih).
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN116875635A (zh) 2015-10-22 2023-10-13 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
CN108697735A (zh) * 2015-11-05 2018-10-23 希望之城公司 用于制备供过继性t细胞疗法用的细胞的方法
US10724006B2 (en) * 2015-11-19 2020-07-28 Novartis Ag Buffers for stabilization of lentiviral preparations
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
WO2017112741A1 (fr) 2015-12-22 2017-06-29 Novartis Ag Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
KR102470979B1 (ko) * 2016-03-16 2022-11-24 넥스이뮨, 인크. 항원 특이적 t-세포의 생산
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN113082201B (zh) * 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
CN106086235A (zh) * 2016-06-22 2016-11-09 宜明细胞生物科技有限公司 一种定性检测car‑t产物中vsvg序列污染的方法
JP7483373B2 (ja) 2016-07-29 2024-05-15 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法
WO2018026953A1 (fr) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation de tcr en utilisant des protéines de fusion
HUE054080T2 (hu) 2016-10-07 2021-08-30 Tcr2 Therapeutics Inc Készítmények és eljárások a T-sejt receptorok átprogramozására fúziós fehérjék felhasználásával
CA3039646A1 (fr) 2016-10-07 2018-04-12 Novartis Ag Recepteurs antigeniques chimeriques pour le traitement du cancer
WO2018085690A1 (fr) 2016-11-04 2018-05-11 Bluebird Bio, Inc. Compositions de lymphocytes t car anti-bcma
CA3044593A1 (fr) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion
EP3574005B1 (fr) 2017-01-26 2021-12-15 Novartis AG Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
EP4501352A3 (fr) 2017-02-28 2025-04-16 Endocyte, Inc. Compositions et procédés pour thérapie par lymphocytes t car
RU2019133280A (ru) 2017-03-22 2021-04-22 Новартис Аг Композиции и способы для иммуноонкологии
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
SG11201909931PA (en) 2017-04-27 2019-11-28 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
CN107287164A (zh) * 2017-07-07 2017-10-24 青岛协和华美医学诊断技术有限公司 靶向cd19的嵌合抗原受体t细胞、制备方法及应用
ES2959953T3 (es) 2017-08-09 2024-02-29 Juno Therapeutics Inc Métodos para producir composiciones celulares genéticamente modificadas y composiciones relacionadas
US20200230221A1 (en) 2017-09-19 2020-07-23 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
CN111629749A (zh) 2017-10-18 2020-09-04 诺华股份有限公司 用于选择性蛋白质降解的组合物和方法
EP4512823A2 (fr) 2017-11-01 2025-02-26 Juno Therapeutics, Inc. Procédé de génération de compositions thérapeutiques de cellules modifiées
SG11202006886VA (en) 2018-01-22 2020-08-28 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Methods of use for car t cells
JP2021511802A (ja) 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬
WO2019165237A1 (fr) 2018-02-23 2019-08-29 Endocyte, Inc. Procédé de séquençage pour thérapie par lymphocytes t à car
WO2019210306A1 (fr) * 2018-04-27 2019-10-31 Momenta Pharmaceuticals , Inc. Préparation de sang
CN108823247A (zh) * 2018-06-05 2018-11-16 山东省医学科学院附属医院 一种人源化cd-19嵌合抗原受体t淋巴细胞载体及其应用
US11608382B2 (en) 2018-06-13 2023-03-21 Novartis Ag BCMA chimeric antigen receptors and uses thereof
WO2020022900A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du rein
CA3106574A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins a base de arid1a, cdkn2a, kmt2b, kmt2d, tp53 et pten contre le cancer
CA3106573A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer colorectal
WO2020022901A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer de l'utérus
CA3106564A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du sein
CN109097396B (zh) * 2018-09-10 2022-10-11 上海细胞治疗集团有限公司 一种制备靶向间皮素的car-t细胞的方法
JP7557882B2 (ja) 2018-09-28 2024-09-30 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (fr) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Méthodes et compositions pour la stimulation de réponses de lymphocytes t endogènes
WO2021108613A1 (fr) 2019-11-26 2021-06-03 Novartis Ag Récepteurs antigéniques chimériques pour cd19 et cd22 et leurs utilisations
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
BR112022018105A2 (pt) 2020-03-10 2022-11-22 Massachusetts Inst Technology Métodos para gerar células nk tipo-memória modificadas e composições das mesmas
CA3173981A1 (fr) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions et procedes pour l'immunotherapie du cancer positif a npm1c
CN115885036A (zh) * 2020-04-03 2023-03-31 米伦纽姆医药公司 提高的病毒转导效率
WO2021221783A1 (fr) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Procédés d'identification de ligands de ciblage de récepteur antigénique chimérique et leurs utilisations
WO2021221782A1 (fr) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Ligands chimériques ciblant des récepteurs antigéniques et leurs utilisations
CN112194728B (zh) * 2020-09-22 2023-07-11 沣潮医药科技（上海）有限公司 用于内毒素清除的嵌合抗原受体及其应用
CN113005223A (zh) * 2020-11-19 2021-06-22 杭州晶佰生物技术有限公司 针对rcr/rcl的数字pcr检测用引物及检测方法
CN112877475A (zh) * 2021-02-19 2021-06-01 北京鼎成肽源生物技术有限公司 一种检测rcl的引物探针组合、试剂盒和检测方法
KR20240099259A (ko) 2021-10-14 2024-06-28 아스널 바이오사이언시스, 인크. 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
WO2023081715A1 (fr) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Association d'une thérapie de lymphocytes car t avec des inhibiteurs de tyrosine kinase de bruton et procédés d'utilisation associés

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
KR100922809B1 (ko) * 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
WO2003013598A2 (fr) * 2001-08-09 2003-02-20 Lam Dominic M K Nouvelles compositions de vaccins et procedes de preparation de vaccins pour des maladies veterinaires et humaines
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
CA2568344C (fr) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Cellules de presentation de nouveaux antigenes artificiels, et utilisations correspondantes
WO2008059553A1 (fr) * 2006-11-13 2008-05-22 Masami Moriyama Procédé de détection du vih-1 sans être affecté par l'anticorps de la protéine anti-souris existant chez l'homme et trousse destinée à une utilisation dans ce procédé
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
SI3006459T1 (sl) * 2008-08-26 2022-01-31 City Of Hope Postopek in sestavki za izboljšano protitumorsko efektorsko delovanje T celic
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer

Also Published As

Publication number Publication date
EA201590216A1 (ru) 2015-04-30
EP2872533A1 (fr) 2015-05-20
AU2017276329A1 (en) 2018-01-18
EP2872533A4 (fr) 2016-04-13
MX2015000439A (es) 2015-12-01
EP2872533B1 (fr) 2019-04-24
CN112375846A (zh) 2021-02-19
CN104619723B (zh) 2020-12-08
AU2017276329B2 (en) 2020-01-23
MX370495B (es) 2019-12-13
AU2013289979A1 (en) 2015-01-22
KR20240000614A (ko) 2024-01-02
JP6482461B2 (ja) 2019-03-13
KR102332322B1 (ko) 2021-12-01
KR20150036087A (ko) 2015-04-07
US9572836B2 (en) 2017-02-21
KR20210149195A (ko) 2021-12-08
AU2020201949A1 (en) 2020-04-23
JP2015532589A (ja) 2015-11-12
US20150190428A1 (en) 2015-07-09
ES2733525T3 (es) 2019-11-29
WO2014011996A1 (fr) 2014-01-16
CN104619723A (zh) 2015-05-13
EP3584256A1 (fr) 2019-12-25
JP2019088317A (ja) 2019-06-13
MX2019015199A (es) 2020-08-03
CA2878862A1 (fr) 2014-01-16
BR112015000505A2 (pt) 2017-06-27
EA028988B1 (ru) 2018-01-31
CA2878862C (fr) 2023-01-10

Similar Documents

Publication Publication Date Title
IN2014DN11156A (fr)
Lu et al. Identification of a CD4 T-cell epitope in the hemagglutinin stalk domain of pandemic H1N1 influenza virus and its antigen-driven TCR usage signature in BALB/c mice
Turner et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Izawa et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70–CD27 pathway in immunity to Epstein-Barr virus infection
IN2014CN02906A (fr)
Buggert et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection
Clute et al. Cross-reactive influenza virus–specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus–associated infectious mononucleosis
Andrews et al. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response
Waickman et al. Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling
Weber et al. T‐follicular helper cells survive as long‐term memory cells
EP4424376A3 (fr) Récepteurs antigéniques chimériques basés sur des anticorps à domaine unique et leurs procédés d'utilisation
IL292650A (en) Costimulatory chimeric antigen receptor t cells targeting il13ra2
Cooper et al. Rapid GMP-compliant expansion of SARS-CoV-2–Specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19
RU2014144143A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
JP2014534207A5 (fr)
MX2014007262A (es) Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
Preite et al. Somatic mutations and affinity maturation are impaired by excessive numbers of T follicular helper cells and restored by Treg cells or memory T cells
Nguyen et al. SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination
EP4413999A3 (fr) Récepteurs d'antigènes chimériques spécifiques de flt3 et leurs procédés d'utilisation
Van Hemelen et al. HLA class II peptide tetramers vs allergen‐induced proliferation for identification of allergen‐specific CD 4 T cells
Mohns et al. Expansion of simian immunodeficiency virus (SIV)-specific CD8 T cell lines from SIV-naive Mauritian cynomolgus macaques for adoptive transfer
Schulz et al. Evaluation of a new microbeads assay for granulocyte antibody detection
Lorenz et al. Unbiased identification of T-cell receptors targeting immunodominant peptide–MHC complexes for T-cell receptor immunotherapy
de Vries et al. Specific CD8+ T‐lymphocytes control dissemination of measles virus
BR112021026406A2 (pt) Receptor de antígeno quimérico com domínio coes-tumulatório 4-1bb